0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Dextran Specificity in Thrombus Inhibition

ROBERT B. SAWYER, MD; JOHN A. MONCRIEF, MC
Arch Surg. 1965;90(4):562-566. doi:10.1001/archsurg.1965.01320100106016.
Text Size: A A A
Published online

IN RECENT years a great deal of attention has been directed to the properties of dextran other than those of volume expansion. Considerable emphasis has been given to dextran in low flow situations7,9,17,19 and in thrombotic states.5,13-15 Attention has centered on the antisludging effects of low molecular weight dextran (40,000 molecular weight)1,3,9,10,14,20 and the antithrombotic properties of clinical dextran (75,000 molecular weight). Work in our laboratories has been primarily directed to the evaluation of clinical dextran in conditions which predispose to thrombosis and thrombus propagation.15

We demonstrated that clinical dextran would significantly inhibit intravascular thrombosis after vein grafts of arteries which are not more than 4 mm to external diameter, and an ability to inhibit the propagation of previously formed thrombi in isolated canine jugular veins. We have also reported on its use in the treatment of thrombophlebitis.15

Since both clinical dextran and low molecular

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();